Ivabradine Accord

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
01-03-2022
Ciri produk Ciri produk (SPC)
01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
01-06-2017

Bahan aktif:

ivabradine hydrochloride

Boleh didapati daripada:

Accord Healthcare S.L.U.

Kod ATC:

C01EB17

INN (Nama Antarabangsa):

ivabradine

Kumpulan terapeutik:

Cardiac therapy

Kawasan terapeutik:

Angina Pectoris; Heart Failure

Tanda-tanda terapeutik:

Symptomatic treatment of chronic stable angina pectorisIvabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm.Ivabradine is indicated :- in adults unable to tolerate or with a contra-indication to the use of beta-blockers- or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.Treatment of chronic heart failureIvabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. (see section 5.1)

Ringkasan produk:

Revision: 6

Status kebenaran:

Authorised

Tarikh kebenaran:

2017-05-22

Risalah maklumat

                                30
B. PACKAGE LEAFLET
31
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
IVABRADINE ACCORD 5 MG FILM-COATED TABLETS
IVABRADINE ACCORD 7.5
MG FILM-COATED TABLETS
ivabradine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Ivabradine Accord is and what it is used for
2.
What you need to know before you take Ivabradine Accord
3.
How to take Ivabradine Accord
4.
Possible side effects
5
How to store Ivabradine Accord
6.
Contents of the pack and other information
1.
WHAT IVABRADINE ACCORD IS AND WHAT IT IS USED FOR
Ivabradine Accord is a heart medicine used to treat:
-
Symptomatic stable angina pectoris (which causes chest pain) in adult
patients whose heart rate
is over or equal to 70 beats per minute. It is used in adult patients
who do not tolerate or cannot
take heart medicines called beta-blockers. It is also used in
combination with beta-blockers in
adult patients whose condition is not fully controlled with a
beta-blocker.
-
Chronic heart failure in adult patients whose heart rate is over or
equal to 75 beats per minute.
It is used in combination with standard therapy, including
beta-blocker therapy or when
beta-blockers are contraindicated or not tolerated.
About stable angina pectoris (usually referred to as “angina”):
Stable angina is a heart disease which happens when the heart does not
receive enough oxygenThe
most common symptom of angina is chest pain or discomfort.
About chronic heart failure:
Chronic heart failure is a heart disease which happens when your heart
cannot pump enough bloo
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Ivabradine Accord 5 mg film-coated tablets
Ivabradine Accord 7.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Ivabradine Accord 5 mg film-coated tablets
Each film-coated tablet contains 5 mg ivabradine (as hydrochloride).
_Excipient with known effect _
Each 5 mg film-coated tablet contains 72 mg lactose (as anhydrous).
Ivabradine Accord 7.5 mg film-coated tablets
Each film-coated tablet contains 7.5 mg ivabradine (as hydrochloride).
_Excipient with known effect _
Each 7.5 mg film-coated tablet contains 108 mg lactose (as anhydrous).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet
Ivabradine Accord 5 mg film-coated tablets
Salmon-coloured, oblong shaped, approximately 8.50 mm in length, 4.50
mm in width, film-coated
tablets scored on both sides, debossed with “FK” on one side and
“2” on other side.
The tablet can be divided into equal doses.
Ivabradine Accord 7.5 mg film-coated tablets
Salmon-coloured, triangular shaped, approximately 7.30 mm in length,
6.80 mm in width, film-coated
tablets debossed with “FK” on one side and “1” on other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Symptomatic treatment of chronic stable angina pectoris
Ivabradine is indicated for the symptomatic treatment of chronic
stable angina pectoris in coronary
artery disease adults with normal sinus rhythm and heart rate ≥ 70
bpm. Ivabradine is indicated:
-
in adults unable to tolerate or with a contraindication to the use of
beta-blockers
-
or in combination with beta-blockers in patients inadequately
controlled with an optimal
beta-blocker dose.
3
Treatment of chronic heart failure
Ivabradine is indicated in chronic heart failure New York Heart
Association (NYHA) II to IV class
with systolic dysfunction, in adult patients in sinus rhythm and whose
heart rate is ≥ 75 bpm, in
combination with standard therapy including beta-blocker therapy or
when beta-blocker
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 01-03-2022
Ciri produk Ciri produk Bulgaria 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 01-06-2017
Risalah maklumat Risalah maklumat Sepanyol 01-03-2022
Ciri produk Ciri produk Sepanyol 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 01-06-2017
Risalah maklumat Risalah maklumat Czech 01-03-2022
Ciri produk Ciri produk Czech 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Czech 01-06-2017
Risalah maklumat Risalah maklumat Denmark 01-03-2022
Ciri produk Ciri produk Denmark 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 01-06-2017
Risalah maklumat Risalah maklumat Jerman 01-03-2022
Ciri produk Ciri produk Jerman 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 01-06-2017
Risalah maklumat Risalah maklumat Estonia 01-03-2022
Ciri produk Ciri produk Estonia 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 01-06-2017
Risalah maklumat Risalah maklumat Greek 01-03-2022
Ciri produk Ciri produk Greek 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Greek 01-06-2017
Risalah maklumat Risalah maklumat Perancis 01-03-2022
Ciri produk Ciri produk Perancis 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 01-06-2017
Risalah maklumat Risalah maklumat Itali 01-03-2022
Ciri produk Ciri produk Itali 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Itali 01-06-2017
Risalah maklumat Risalah maklumat Latvia 01-03-2022
Ciri produk Ciri produk Latvia 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 01-06-2017
Risalah maklumat Risalah maklumat Lithuania 01-03-2022
Ciri produk Ciri produk Lithuania 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 01-06-2017
Risalah maklumat Risalah maklumat Hungary 01-03-2022
Ciri produk Ciri produk Hungary 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 01-06-2017
Risalah maklumat Risalah maklumat Malta 01-03-2022
Ciri produk Ciri produk Malta 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Malta 01-06-2017
Risalah maklumat Risalah maklumat Belanda 01-03-2022
Ciri produk Ciri produk Belanda 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 01-06-2017
Risalah maklumat Risalah maklumat Poland 01-03-2022
Ciri produk Ciri produk Poland 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Poland 01-06-2017
Risalah maklumat Risalah maklumat Portugis 01-03-2022
Ciri produk Ciri produk Portugis 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 01-06-2017
Risalah maklumat Risalah maklumat Romania 01-03-2022
Ciri produk Ciri produk Romania 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Romania 01-06-2017
Risalah maklumat Risalah maklumat Slovak 01-03-2022
Ciri produk Ciri produk Slovak 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 01-06-2017
Risalah maklumat Risalah maklumat Slovenia 01-03-2022
Ciri produk Ciri produk Slovenia 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 01-06-2017
Risalah maklumat Risalah maklumat Finland 01-03-2022
Ciri produk Ciri produk Finland 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Finland 01-06-2017
Risalah maklumat Risalah maklumat Sweden 01-03-2022
Ciri produk Ciri produk Sweden 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 01-06-2017
Risalah maklumat Risalah maklumat Norway 01-03-2022
Ciri produk Ciri produk Norway 01-03-2022
Risalah maklumat Risalah maklumat Iceland 01-03-2022
Ciri produk Ciri produk Iceland 01-03-2022
Risalah maklumat Risalah maklumat Croat 01-03-2022
Ciri produk Ciri produk Croat 01-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Croat 01-06-2017

Cari amaran yang berkaitan dengan produk ini